FIELD: medicine.
SUBSTANCE: reproduction of human diseases in the experiment. Invention can be used to simulate disorders of the coagulation link of the hemostasis system under conditions of bacterial inflammation and pulmonary thrombosis. E. coli lipopolysaccharide is administered intratracheally at a dose of 0.5 mg/kg to male and female outbred rats. Then, an hour later, a 3% solution of thromboplastin is administered intravenously in a volume of 0.3 ml. On the 7th day after the administration of the medicinal products, blood is taken and the indicators of the activity of the coagulation link of hemostasis are analyzed.
EFFECT: invention provides a clinical picture of hemostasis system disorders in case of lung injury as a result of pulmonary vascular thrombosis against the background of bacterial inflammation.
1 cl, 2 dwg, 1 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF MODELING HEMOSTASIS SYSTEM DISORDERS | 2019 |
|
RU2714597C1 |
MEDICINAL PRODUCT WITH ANTICOAGULANT (INHIBITOR OF FACTOR IIA), ANTITHROMBOTIC, ANTI-INFLAMMATORY ACTIVITIES AND CONTAINING 5,7-DI(THIOPHEN-2-IL)-4,5-DIHYDRO-[1,2,4]TRIAZOLO[1,5-a ]PYRIMIDINE | 2022 |
|
RU2798587C1 |
METHOD FOR CORRECTING HEMOSTASIS DISORDERS IN CASE OF VAST OPERATIONS UPON ORGANS OF HEPATOPANCREATODUODENAL AREA | 2004 |
|
RU2279853C2 |
METHOD FOR MODELING ACUTE LUNG INJURY CASES | 2004 |
|
RU2285961C2 |
METHOD FOR SIMULATING A COMBINED PATHOLOGY OF METABOLIC SYNDROME AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 2019 |
|
RU2714679C1 |
METHOD FOR SIMULATING THROMBUS FORMATION IN MICE FOR ASSESSING EFFECT OF ANTICOAGULANT PREPARATIONS | 2014 |
|
RU2570162C1 |
BISAMIDE DERIVATIVE OF DICARBOXYLIC ACID AS AGENT STIMULATING TISSUE REGENERATION AND RESTORATION OF REDUCED FUNCTIONS OF TISSUES | 2016 |
|
RU2727142C2 |
ANTICOAGULANT DRUG, WHICH IS A SYNTHETIC DIPEPTIDE Ac-Trp-Arg-Pip·HCl, A PHARMACEUTICAL COMPOSITION COMPRISING SAID ANTICOAGULANT DRUG | 2019 |
|
RU2712194C1 |
RADIOPAQUE PREPARATION | 2011 |
|
RU2448732C1 |
METHOD FOR CORRECTING HYPERCOAGULABLE STATE WHEN ANTITUMOR DRUG CISPLATIN IS ADMINISTERED BY INJECTION | 2020 |
|
RU2743848C1 |
Authors
Dates
2023-07-25—Published
2023-01-11—Filed